Can a maintenance drug keep lymphoma at bay? new trial aims to find out.

NCT ID NCT07654465

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether giving rituximab maintenance therapy after initial treatment with rituximab and lenalidomide (R2) can improve outcomes for people with untreated marginal zone lymphoma. About 144 patients who respond to R2 will be randomly assigned to receive rituximab every 8 weeks for 2 years or just observation. The main goal is to see if maintenance therapy extends the time without the disease getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab and lenalidomide
What this could lead to: If successful, this could show that maintenance therapy with rituximab helps keep marginal zone lymphoma in check longer after initial treatment.
What could go wrong: This is a phase 2 trial with only 144 participants, so results are preliminary. The maintenance therapy may not improve outcomes and could increase side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA (MZL)

Contacts and locations

Locations

Sun yat-sen university cancer center

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.